Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
01 oct. 2024 10h51 HE
|
Spherix Global Insights
EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...
Asbestos Contamination in Everyday Talc Fuels Alarm and Health Concerns Among U.S. Women
19 sept. 2024 08h00 HE
|
The Law Offices of Justinian C. Lane, Esq. PLLC
Asbestos Contamination in Everyday Talc Fuels Alarm and Health Concerns Among U.S. Women
Pain Management Market is anticipated to register a CAGR of 7.39% during 2023 - 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
31 mars 2023 09h00 HE
|
Mordor Intelligence
Hyderabad, March 31, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Pain Management Market - (2023 – 2028),” the market is expected to register a CAGR of 7.39%. The...
Flow Diverters Market to Hit $1.04 Billion, with CAGR of 15.3% by 2031: Allied Market Research
27 nov. 2022 19h00 HE
|
Allied Market Research
Portland, OR, Nov. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Flow Diverters Market generated $251.50 million in 2021, and is...
Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting
11 août 2020 08h01 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05 févr. 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...